Mangoceuticals, Inc. Common Stock (MGRX) — Cash Flow-to-Debt Ratio
Latest as of June 2026:
-0.16x
Mangoceuticals, Inc. Common Stock (MGRX) has a Cash Flow-to-Debt Ratio of -0.16x as of June 2026, meaning its operating cash flow of $-260.51K could theoretically repay 0% of its total liabilities ($1.65 Million) in one year. See MGRX financial flexibility score to measure the company's free cash flow as a share of total liabilities.
CF-to-Debt Ratio
-0.16x
Operating CF / Total Liabilities
Operating Cash Flow
$-260.51K
USD
Total Liabilities
$1.65 Million
USD
Data as of
Jun 2026
Most recent filing
Mangoceuticals, Inc. Common Stock Cash Flow-to-Debt Ratio (2021–2025)
Historical debt coverage capacity for Mangoceuticals, Inc. Common Stock across 5 annual periods. For the full cash flow conversion analysis, see MGRX cash generation efficiency.
Annual Cash Flow-to-Debt Ratio for Mangoceuticals, Inc. Common Stock (2021–2025)
Year-by-year debt coverage analysis for Mangoceuticals, Inc. Common Stock.
| Year | CF-to-Debt Ratio | Operating CF (USD) | Total Liabilities | YoY Change |
|---|---|---|---|---|
| 2025 | -6.57x | $-5.85 Million | $890.57K | ▼ -92.5% |
| 2024 | -3.41x | $-4.86 Million | $1.43 Million | ▲ +86.5% |
| 2023 | -25.35x | $-7.00 Million | $276.04K | ▼ -632.8% |
| 2022 | -3.46x | $-1.35 Million | $389.26K | ▼ -675.4% |
| 2021 | -0.45x | $-17.52K | $39.27K | — |
Cash Flow-to-Debt Ratio = Operating Cash Flow / Total Liabilities. Higher is better for debt service capacity.